Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.76 |
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440848 | 0.88 | PGR (0.61) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL6799157 | 0.87 | RAB9A (1.00) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL2021051 | 0.87 | MEN1 (0.57) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL21674204 | 0.87 | MEN1 (0.57) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL13952165 | 0.86 | NPC1 (0.78) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL2894685 | 0.86 | NPC1 (0.65) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL19234508 | 0.86 | NPC1 (0.78) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL28246369 | 0.85 | NPC1 (0.76) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL12514183 | 0.84 | PGR (0.56) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL8867499 | 0.84 | NPC1 (0.73) | NPC1RAB9ATP53SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | NPC1 240/4885RAB9A 1850/4885TP53 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.